Fear and Greed

12:31 p.m. EST

Of the two emotions, fear is easier to trade.

Trading professionals prefer down markets.

Even in his trading video, the late David Weis remarks … ‘I have a preference for down markets …’

Profits come nearly twice as fast and the bottom is easier to detect.

With that in mind, the daily chart of inverse biotech fund LABD, has been noted showing both emotions:

Extreme fear shows up as spikes at the trend line. Also noticeable, the spikes are widely spaced.

Greed on the other hand, is spaced closer and harder to detect. Remember, we’re looking at the inverse (LABD); fear and greed locations are swapped.

Moving on to the set-up, the Wyckoff spring:

Considering the current situation … i.e. valuations, margin debt, retail participation extremes, the above forecast is a modest one.

A potential doubling in value (measured move).

The expectation is for LABD to contact the upper trading range somewhere around 27.50 (not advice, not a recommendation).

If it does and then breaks to the upside, a standard measured move (trading range distance, magenta lines) would target the 40-area.

At this juncture, the market (SPBIO) is giving no overt indication of imminent collapse.

This is how markets work.

If we do get the expected wipeout, be prepared for the usual suspects to come out and say ‘No one saw it coming.’

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Iceberg … Dead Ahead

12:32 p.m. EST

Time and technical have come together; indicating potential downside collapse in biotech.

Collapse potential is immense and has been for years.

Fibonacci 55 days after the 2/10/21, highs, biotech (SPBIO), pivots decisively lower.

Of all the major indices, biotech on a percentage basis, is the downside leader.

Rightly so.

Fundamentally, it’s poised to disintegrate with its illegal, Mengele style campaign of medical experimentation.

Who knows if that full disclosure will happen.

The ‘controllers’, the oligarchs, may come up with some other mechanism to usurp the media, the internet and keep it all under wraps.

However, it looks like the tide’s turning.

Remember, the market leads the news; not the other way around.

If biotech goes into its well deserved collapse, downside action itself will be the catalyst for exposure.

For now, SPBIO is pivoting lower; LABD higher.

The daily chart of LABD shows the Fibonacci time relationship. From low to low; Fibonacci 55 days.

Yesterday, the 28th, was Day 55.

Today, LABD has already posted a new daily high … weighting probability to more upside (SPBIO, lower).

The next chart has the potential trading channel.

It looks aggressive.

However, the market itself has defined the trend.

Shown, in pervious updates, this trend angle has been repeated at least four times from March 5th, LABD high, to yesterday’s low.

It’s no guarantee. We’ll let subsequent price action confirm or negate the right side trend.

As of this post, LABD continues to push aggressively higher.

Our ‘project’ has an open position in LABD.

Without revealing specifics of that position (discussed previously), it’s represented in the table below:

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Another Brick … in Biotech

4:36 p.m. EST: Updated with additional data below in red

10:26 a.m. EST:

If the adverse event database can be trusted (a question in itself), the number of people recently injected with ‘speck’ protection, has fallen off a cliff.

The April 16th update linked here, had this to say:

“You would think it’s just a matter of time before this reaches some kind of tipping point; where enough of the herd realizes all at once, the lie.”

The abrupt halt in reaction uploads would indicate a jump in collective awareness the ‘speck’ is a lie … just in time for the next ‘event’ (likely to be food supply or cyber disruption).

Before we get to any market analysis, there’s one more thing concerning biotech … the masks.

Since investigative reporting has been usurped by controlling entities pushing false narratives, information now has to come from the individual(s).

That data is typically in raw form; unlike the slick presentations (i.e. lies) we’ve grown used to on the mainstream.

It’s now up to the researcher to do the leg-work on what’s real or not.

However, this link, appears to be above-board. Download the file if your viewer will not work.

A medical professional has investigated (internet rumored) mask contamination and has found disturbing results.

She is visibly shaken by her findings … probably realizing for the first time, the level of evil that’s directing controlling interests, world events.

She can’t fathom that someone would intentionally put parasites in a product that’s being pushed by the mainstream for us (and children) to wear ‘two … or three’.

Unfortunately, that’s where we are.

This author knows for a fact, a certain big-box home improvement store, handed out boxes of these same (type of) masks ‘for free’ to its employees.

When those employees for the most part, refused to wear them …. it then became a corporate directive, subject to termination.

Most of those employees eventually replaced the paper with a nylon-based covering. However, looking at the video, it seems like just one exposure to the paper masks is enough to inflict unknown levels of harm.

Intentional parasitic contamination … one more brick, in biotech.

Update: A contrary opinion is here:

Harmless textile fibers.’

You’ll have to make your own call. Both sides (parasites non parasite) are presented in this update.

Since the author of these posts has never worn a toilet-paper mask (or any mask), what’s on them does not apply from a personal standpoint.

Nonetheless, many in the public can be seen using this type of so-called protection.

Either way, the technical condition of biotech remains …

Moving on to the markets:

The chart of LABD (3X Inverse SPBIO), continues to move higher.

Our project position is being maintained (see table) and the stop has been moved up as shown:

Obviously, there’s a lot going on in the markets and elsewhere. There’s no telling when or if it will all break loose.

No matter; If that happens, we’re positioned (not advice, not a recommendation) in a market that’s already moving lower … pushing LABD higher.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech Demolition

You have to wonder; once the ruling oligarchs are finished with the first (‘speck’) round, moving on to the next fabricated crisis, if biotech’s not going to be thrown under the bus.

After all, its served its purpose.

According to comments posted beneath this article, about 33%, of the U.S. population have (apparently, voluntarily) injected themselves.

According to this link, it’s about 24%, of the population.

Either way, it’s a lot … in the tens of millions.

It’s a crazy business model; systematically destroy your customer base.

Said many times in these updates, attempting to match fundamentals to technicals is usually not successful.

Sector Analysis:

Referring back to Ed Seykota, in his ‘Market Wizards‘ interview, he said using fundamentals as a basis for positioning, rarely if ever, worked.

Still, it’s undeniable something very wrong is going on in the sector.

Our market table has been updated and we’ve included the S&P Biotech Sector, SPBIO:

All markets are within fractions of a percent of all time highs except for semis, mid-caps and biotech.

The S&P biotech is down a whopping, 25%.

It’s already well in bear market territory.

Positioning:

Since we’re working the short side (not advice, not a recommendation), the focus is on biotech and specifically LABD.

The fund attempts to track the 3X inverse of SPBIO.

With that kind of leverage, LABD has significant downside bias. Positioning (from experience) is best suited when the move is sustainable and persistent.

Looking at the chart of LABD, we could be there. At this time, the fund is trending higher at a stiff +820%, on an annualized basis.

Project Stimulus:

Our Project account is positioned as shown. Since the account’s not large enough to enable leverage as determined by the broker, we just have to wait it out till it gets there (currently set at $2,000).

Summary:

Stated in The Rich And The Super Rich (if memory serves), not since Marie Antionette have the ruling oligarchs allowed themselves to be out in the open.

Seems like her demise cured them of having to get (direct) attention.

That would mean, people in the public eye at this point, are just useful idiots. And when their usefulness has run its course … ???

From watching them, it’s obvious they’re delusional … thinking they can tame evil (even harming children) and escape wrath.

“And for this cause God shall send them strong delusion, that they should believe a lie:”

The entire ‘transhumanism’ agenda is an attempt to cheat death … to avoid judgement … to outsmart the almighty.

Good luck with that.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Amgen: Fakeout-Breakout?

11:56 a.m. EST:

Amgen’s sotorasib news could be its all time high.

Immediately following that announcement, AMGN went into a 20% decline (‘sign of supply’).

In Wyckoff terms, we can look at the action from late January to now as a massive ‘up-thrust’ (false breakout).

That up-thrust is now being tested … with another breakout attempt.

If that’s the case and the test fails with price action retreating from here, then AMGN’s set-up for a significant downward reversal.

Significant in that we’re not (ever) coming back to these levels.

That statement might seem hyperbolic and it very well could be.

However, when one looks at reports like this, insiders are bailing out; leaving “retail” holding the bag as usual.

Fundamentals:

Although not directly related to AMGN, we have yet another horror show in the biotech arena.

The wheels are falling off the ‘speck’ false narrative; tragically so.

The following is taken from the comment section of the video post:

From the guy who filmed :

“Less than 5 minutes from getting God knows what injected inside them the two people to my left starting having seizures. First the gentlemen in the red car was watching in shock as the driver next to him was having a seizure. Little did he know he would have one right after him. I called the medics to help him. They have a procedure where after you get the shot you have to wait in the car for 15 min and if something goes wrong to honk your horn and someone will show up. Well these folks to my left just passed out into seizures with no warning.

You would think it’s just a matter of time before this reaches some kind of tipping point; where enough of the herd realizes all at once, the lie.

Positioning:

The last post has us breaking the rules. Was that the right thing to do?

This morning’s price action has the answer: Yes.

The Project Stimulus table has been updated to include the new (hard) stop level. With LABD currently up a good 5.50%, and looking to move higher, it’s not likely the stop will be hit.

There is one caveat: As of this post, IBB has not printed a new daily low. That leaves the (slight) possibility open for a move higher.

Several attempts have been made to short biotech via LABD (not advice, not a recommendation). It looks like the current attempt is underway.

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Breakin’ the Law

12:09 p.m. EST:

‘Know when to break the rules’

‘Always follow the rules’ was the admonition of Ed Seykota.

Almost in the very next sentence of his interview he said, ‘know when to break the rules’.

Could this be it?

At trader’s discretion, we’re maintaining short biotech via LABD (not advice, not a recommendation).

More analysis to follow.

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

What is Risk?

9:06 a.m. EST:

Each retrace higher in biotech (IBB) has a lower top.

Right now, risk has been squeezed down to the hash-marked area on the chart.

It’s the distance between 153.84 and 153.15, just 0.69-points.

A push past the previous retrace high of 153.84, means IBB is now sub-dividing higher; exiting the current short position is warranted (not advice, not a recommendation).

Pre-market action has IBB trading higher but below the last session high.

This juncture, 0.69-points from subdividing higher or reversal, is a low risk area; the distance from exiting or maintaining short is narrow.

The daily chart below has price action with Fibonacci projections.

Yesterday, IBB touched and reversed from the 50% projected level … thus giving it some amount of validation.

As sated in previous updates (from empirical observation), if price action gets to the 50% level, it tends to continue on to at least a 61.8%.

We’ll see if that’s the case here.

Fundamentals and News:

Fundamentally, the wheels continue to fall off the narrative.

Yet again, we have posts like this showing the devastation of experimental gene ‘therapy’.

Here’s another horror show.

Positioning:

The ‘Project’ remains short the sector via LABD (not advice, not a recommendation). The stop may have been moved up too quickly (a possible error), so we’ll see what happens with early action.

Summary:

We’re at the edge where IBB either posts higher and continues with a bull move or it stalls and reverses.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Time’s Getting Short

2:11 p.m. EST:

We’re looking at biotech fund LABD (3X inverse IBB).

The case has already been made in a previous update, IBB upward bounces off support (on a weekly close basis), are traveling less distance.

Now, it looks like there’re reversing more quickly as well.

Each retrace move is taking less time. LABD has gone from twelve days before continuation, to four days …. and now, maybe just two?

This morning’s biotech IBB, action is either a reversal to more upside or it’s a short squeeze.

Long term momentum indicators remain down for IBB.

Probabilities point to a squeeze; especially so, if IBB continues to retrace lower into the close.

Fundamentals:

On that front, cracks continue to appear. Today and yesterday we have ‘speck’ therapy adverse reaction and outright ban actions being implemented.

As Reiner Fuellmich stated in his interview (link here), there’s a lot of infighting amongst the ruling oligarchs.

With such greed, avarice and deceit on full display, one can’t expect everyone (of them) to be operating in concert.

Positioning:

Our Project got stopped out with a profit early in the session. Based on the above data, that position, LABD has been re-entered (not advice not a recommendation):

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Pre-Market

9:13 a.m. EST: Since the ‘project’s’ positioned short biotech, that’s the focus for the morning.

The last two updates, here and here, showed biotech acting differently than other markets.

With IBB currently down nearly -15%, from its all time print high, it’s already in ‘correction’ territory; just a few percent more, it’ll be classified as ‘bear market’.

The weekly close shows another bearish set-up with what looks like a Head & Shoulders pattern. Note the second ‘bounce’ off the neckline was markedly lower than the first.

Energy to the upside is dissipating. Price action may be ready to penetrate the neckline.

As of this post, inverse fund LABD is trading unchanged to slightly higher (on about 24,000 shares).

If there’s a decisive move lower in IBB (higher LABD), we’ll change the LABD stop. With a current stop at 22.96, (not advice, not a recommendation) we’re right at break even.

Truth Begins to Surface

Stated many times on this site, with such a big (world-wide) lie, it’ll be hard to keep the truth under wraps … especially so, when scenes like this are everyday events.

Several corporations in the IBB sector, are providing the public ‘service’ shown in the above link. We’ll go into their technical condition in a separate update.

Stay Tuned

Charts by StockCharts

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.

Biotech … Down, Down, Down

Momentum:

Monthly, weekly and daily MACD histogram, all down.

We’ll look at several daily charts before moving on to weekly and P&F.

Above, the Head & Shoulders pattern is clear. There’s a down-sloping neckline with a rally that looks to be rolling over.

An alternate view are two wedge patterns:

On to the weekly. A Fibonacci projection has been added showing down move potential.

Lastly, daily P&F with its own projections.

Interesting to note: Range from 104 – 127, closely matches the 100.0% – 161.8%, Fibonacci range of 108.50 – 128:

From the previous update, biotech IBB, appears to have broken from the crowd. Momentum indicators on multiple timeframes have all lined up to the downside.

Friday’s after-market activity (BigCharts), has IBB down -0.84, on a solid 1,035,712, shares.

If the aftermarket volume is correct (no misprints or errors), it’s equivalent to 25% , of the entire volume for the day’s regular session.

Stay Tuned

Note:  Posts on this site are for education purposes only.  They provide one firm’s insight on the markets.  Not investment advice.  See additional disclaimer here.